A prospective study of interferon therapy modified by pre-treatment viral load in cirrhotic patients

Liver

Volumn 20, Issue 4, 2000, Pages 271-280

  Shiratori, Yasushi ^a   Moriyama, Mistuhiko ^b   Imazeki, Fumio ^c   Ohkubo, Hitoshi ^b   Tanaka, Naohide ^b   Arakawa, Yasuyuki ^b   Yoshida, Haruhiko ^a   Yokosuka, Osamu ^c   Shibuya, Akitaka ^d   Matsuzaki, Kohei ^e   Hashimoto, Etsuko ^f   Hayashi, Naoaki ^f   Hirata, Keiichi ^g   Ohashi, Yasuo ^a   Omata, Masao ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c CHIBA UNIVERSITY   (Japan)

^d KITASATO UNIVERSITY   (Japan)

^e TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^g SAITAMA RED CROSS HOSPITAL   (Japan)

Author keywords

Cirrhosis; HCV RNA levels; HCV subtypes; Hepatitis C virus; Interferon

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; VIRUS RNA;

ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0033944684     PISSN: 01069543     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0676.2000.020004271.x     Document Type: Article

References (42)

1. Natural history of liver fibrosis progression in patients with chronic hepatitis C
2. Hepatitis C. the clinical spectrum of disease
3. Natural history of hepatitis C
4. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma
5. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus
6. Hepatocellular carcinoma in Italian patients with cirrhosis
7. Risk factor for hepatocellular carcinoma among patients with chronic liver disease
8. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: A prospective study of 251 patients
9. Hepatitis C and hepatocellular carcinoma
10. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: A preliminary report
11. Treatment of hepatitis C with recombinant interferon-alpha: A multicenter randomized, controlled trial
12. Recombinant interferon alpha therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial
13. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C
14. Factors predictive of response to interferon-alfa therapy in hepatitis C virus infection
15. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotypes are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C
16. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection
17. The treatment of chronic viral hepatitis
18. Quantitative assays for hepatitis C virus in serum as predictors of the long-term response to interferon
19. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
20. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis
21. Interferon treatment of cirrhotic patients with chronic hepatitis C
22. Therapy of hepatitis C: Patients with cirrhosis
23. Classification of chronic hepatitis: Diagnosis, grading and staging
24. Cirrhosis
25. Quantification of hepatitis C virus by competitive reverse transcriptase polymerase chain reaction
26. Full-length sequence of a hepatitis C virus genome having poor homology to reported isolated: Comparative study of four distinct genotypes
27. Proposed system for the nomenclature of hepatitis C viral genotypes
28. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment
29. Correlation of biochemical response to interferon alfa with histological improvement in hepatitis: A meta-analysis of diagnostic test characteristics
30. Discrepancy between biochemical and virological responses to interferon- alfa in chronic hepatitis C
31. How soon can a virological sustained response be determined after withdrawal of interferon therapy in chronic hepatitis C?
32. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment
33. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C
34. Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6 or 12 months: A 4-year follow-up of 211 patients
35. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alfa 2b for 60 weeks
36. Interferon-alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
37. Randomized trial of interferon alfa2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
38. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
39. Randomized trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis with cirrhosis
40. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV- related liver cirrhosis
41. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C
42. Effect of interferon-alfa on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study